酒精性肝病

World Health Organization. Public health problems caused by harmful use of alcohol: report by the Secretariat. Fifty-eighth World Health Assembly, Provisional agenda item 13.14. Geneva, Switzerland: WHO; 2005.

• 全文

O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010 Jan;51(1):307-28.

• 全文
• 摘要

Heimbach J, Kulik LM, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-80.

• 全文
• 摘要

Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997 Jan;25(1):108-11.

• 全文
• 摘要

1.  The Health and Social Care Information Centre. Statistics on alcohol: England, 2015. Jun 2015 [internet publication].

• 全文

2.  World Health Organization. Global status report on alcohol and health 2014. 2014 [internet publication].

• 全文

3.  World Health Organization. Public health problems caused by harmful use of alcohol: report by the Secretariat. Fifty-eighth World Health Assembly, Provisional agenda item 13.14. Geneva, Switzerland: WHO; 2005.

• 全文

4.  Welch C, Harrison D, Short A, et al. The increasing burden of alcoholic liver disease on United Kingdom critical care units: secondary analysis of a high quality clinical database. J Health Serv Res Policy. 2008 Apr;13(suppl 2):40-4.

• 摘要

5.  Sand J, Välikoski A, Nordback I. Alcohol consumption in the country and hospitalizations for acute alcohol pancreatitis and liver cirrhosis during a 20-year period. Alcohol Alcohol. 2009 May-Jun;44(3):321-5.

• 摘要

6.  Saunders JB, Latt N. Epidemiology of alcoholic liver disease. Baillieres Clin Gastroenterol. 1993 Sep;7(3):555-79.

• 摘要

7.  Loft S, Olesen KL, Dossing M. Increased susceptibility to liver disease in relation to alcohol consumption in women. Scand J Gastroenterol. 1987 Dec;22(10):1251-6.

• 摘要

8.  Lelbach WK. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann N Y Acad Sci. 1975;252:85-105.

• 摘要

9.  Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol. 2009;15:3462-3471.

• 摘要

10.  Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002 Mar;35(3):635-8.

• 全文
• 摘要

11.  Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992;136:1248-1257.

• 摘要

12.  Gleeson D, Bradley MP, Jones J, et al. Cytokine gene polymorphisms in heavy drinkers with and without decompensated liver disease: a case-control study. Am J Gastroenterol. 2008;103:3039-3046.

• 摘要

13.  Cichoz-Lach H, Partycka J, Nesina I, et al. The influence of genetic polymorphism of CYP2E1 on the development of alcohol liver cirrhosis [in Polish]. Wiad Lek. 2006;59:757-761.

• 摘要

14.  Cichoz-Lach H, Partycka J, Nesina I, et al. Genetic polymorphism of alcohol dehydrogenase 3 in alcohol liver cirrhosis and in alcohol chronic pancreatitis. Alcohol Alcohol. 2006;41:14-17.

• 全文
• 摘要

15.  Li Y, Zhou J. Roles of silent information regulator 1-serine/arginine-rich splicing factor 10-lipin 1 axis in the pathogenesis of alcohol fatty liver disease. Exp Biol Med (Maywood). 2017 Jun;242(11):1117-25.

• 全文
• 摘要

16.  Mendenhall CL, Seeff L, Diehl AM, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119). Hepatology. 1991;14:581-589.

• 摘要

17.  Caldwell SH, Li X, Rourk RM, et al. Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol. 1993;88:1016-1021.

• 摘要

18.  Seitz HK, Stickel F. Alcoholic liver disease in the elderly. Clin Geriatr Med. 2007;23:905-921, viii.

• 摘要

19.  Polednak AP. Temporal trend in the U.S. black-white disparity in mortality rates from selected alcohol-related chronic diseases. J Ethn Subst Abuse. 2008;7:154-164.

• 摘要

20.  Buchsbaum DG, Buchanan RG, Centor RM, et al. Screening for alcohol abuse using CAGE scores and likelihood ratios. Ann Intern Med. 1991 Nov 15;115(10):774-7.

• 摘要

21.  Girela E, Villanueva E, Hernandez-Cueto C, et al. Comparison of the CAGE questionnaire versus some biochemical markers in the diagnosis of alcoholism. Alcohol Alcohol. 994 May;29(3):337-43.

• 摘要

22.  O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010 Jan;51(1):307-28.

• 全文
• 摘要

23.  Aalto M, Alho H, Halme JT, et al. AUDIT and its abbreviated versions in detecting heavy and binge drinking in a general population survey. Drug Alcohol Depend. 2009 Jul 1;103(1-2):25-9.

• 摘要

24.  Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J Gastroenterol. 2009 Jan 7;15(1):67-80.

• 全文
• 摘要

25.  Haffner HT, Becker IS, Mann K. The sensitivity of clinico-chemical markers of alcoholism following short-term motivated alcohol abstinence [in German]. Blutalkohol. 1989 Mar;26(2):114-22.

• 摘要

26.  Yersin B, Nicolet JF, Dercrey H, et al. Screening for excessive alcohol drinking: comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med. 1995 Sep 25;155(17):1907-11.

• 摘要

27.  Stauber RE, Stepan V, Trauner M, et al. Evaluation of carbohydrate-deficient transferrin for detection of alcohol abuse in patients with liver dysfunction. Alcohol Alcohol. 1995 Mar;30(2):171-6.

• 摘要

28.  Lumeng L. New diagnostic markers of alcohol abuse. Hepatology. 1986 Jul-Aug;6(4):742-5.

• 摘要

29.  Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol. 2005 Feb;3(2):167-74.

• 摘要

30.  Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007 Oct 15;7:40.

• 摘要

31.  Chrostek L, Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol. 2014 Jul 7;20(25):8018-23.

• 全文
• 摘要

32.  Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess. 2007 Sep;11(34):1-206.

• 全文
• 摘要

33.  Heimbach J, Kulik LM, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-80.

• 全文
• 摘要

34.  Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1214-20.

• 摘要

35.  Bonekamp S, Kamel I, Solga S, et al. Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? J Hepatol. 2009 Jan;50(1):17-35.

• 摘要

36.  European Association for the Study of the Liver. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015 Jul;63(1):237-64.

• 全文
• 摘要

37.  Pavlov CS, Casazza G, Nikolova D, et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev. 2015 Jan 22;(1):CD010542.

• 全文
• 摘要

38.  McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998 Nov;93(11):2022-36.

• 全文
• 摘要

39.  Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med. 1989 Sep 15;111(6):473-8.

• 摘要

40.  Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology. 1996 Jun;110(6):1847-53.

• 摘要

41.  Bell H, Tallaksen CM, Try K, et al. Carbohydrate-deficient transferrin and other markers of high alcohol consumption: a study of 502 patients admitted consecutively to a medical department. Alcohol Clin Exp Res. 1994 Oct;18(5):1103-8.

• 摘要

42.  Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002 Jul 2;137(1):1-10.

• 摘要

43.  Cohen JA, Kaplan MM. The SGOT/SGPT ratio - an indicator of alcoholic liver disease. Dig Dis Sci. 1979 Nov;24(11):835-8.

• 摘要

44.  Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009 Jul;30(1):37-47.

• 摘要

45.  U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore, MD: Williams and Wilkins; 1996.

46.  Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990 Nov 21;264(19):2511-8.

• 摘要

47.  Hoeksema HL, de Bock GH. The value of laboratory tests for the screening and recognition of alcohol abuse in primary care patients. J Fam Pract. 1993 Sep;37(3):268-76.

• 摘要

48.  Berry PA, Thomson SJ, Rahman TM, et al. Review article: towards a considered and ethical approach to organ support in critically-ill patients with cirrhosis. Aliment Pharmacol Ther. 2013 Jan;37(2):174-82.

• 全文
• 摘要

49.  Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec's cirrhosis: influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med. 1968 Mar;44(3):406-20.

• 摘要

50.  Veldt BJ, Laine F, Guillygomarc'h A, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol. 2002 Jan;36(1):93-8.

• 摘要

51.  US Department of Health and Human Services. Incorporating alcohol pharmacotherapies into medical practice. TIP 49. 2009 [internet publication].

• 全文

52.  Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997 Jan;25(1):108-11.

• 全文
• 摘要

53.  Umemura T, Ichijo T, Matsumoto A, et al. Severe hepatic injury caused by orlistat. Am J Med. 2006 Aug;119(8):e7.

• 摘要

54.  Wakim-Fleming J, Mullen KD. Long-term management of alcoholic liver disease. Clin Liver Dis. 2005 Feb;9(1):135-49.

• 摘要

55.  McCullough AJ, Tavill AS. Disordered energy and protein metabolism in liver disease. Semin Liver Dis. 1991 Nov;11(4):265-77.

• 摘要

56.  McCullough AJ, Bugianesi E. Protein-calorie malnutrition and the etiology of cirrhosis. Am J Gastroenterol. 1997 May;92(5):734-8.

• 摘要

57.  Ghorbani Z, Hajizadeh M, Hekmatdoost A. Dietary supplementation in patients with alcoholic liver disease: a review on current evidence. Hepatobiliary Pancreat Dis Int. 2016 Aug;15(4):348-60.

• 摘要

58.  Rosato V, Abenavoli L, Federico A, et al. Pharmacotherapy of alcoholic liver disease in clinical practice. Int J Clin Pract. 2016 Feb;70(2):119-31.

• 摘要

59.  Barve A, Khan R, Marsano L, et al. Treatment of alcoholic liver disease. Ann Hepatol. 2008 Jan-Mar;7(1):5-15.

• 摘要

60.  Swart GR, Zillikens MC, van Vuure JK, et al. Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. BMJ. 1989 Nov 11;299(6709):1202-3.

• 全文
• 摘要

61.  Verboeket-Van De Venne WP, Westerterp KR, Van Hoek B, et al. Habitual pattern of food intake in patients with liver disease. Clin Nutr. 1993 Oct;12(5):293-7.

• 摘要

62.  Antar R, Wong P, Ghali P. A meta-analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. Can J Gastroenterol. 2012 Jul;26(7):463-7.

• 摘要

63.  Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;(5):CD001939.

• 全文
• 摘要

64.  Rambaldi A, Saconato HH, Christensen E, et al. Systematic review: glucocorticosteroids for alcoholic hepatitis - a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther. 2008 Jun;27(12):1167-78.

• 摘要

65.  Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med. 1989 May 1;110(9):685-90.

• 摘要

66.  Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011 Feb;60(2):255-60.

• 摘要

67.  Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med. 1992 Feb 20;326(8):507-12.

• 全文
• 摘要

68.  Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978 Aug;75(2):193-9.

• 摘要

69.  Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 2003 Dec;38(6):1363-9.

• 全文
• 摘要

70.  Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun;45(6):1348-54.

• 全文
• 摘要

71.  Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med. 1990 Aug 15;113(4):299-307.

• 摘要

72.  Mathurin P. Is alcoholic hepatitis an indication for transplantation? Current management and outcomes. Liver Transpl. 2005 Nov;(11 suppl 2):S21-4.

• 全文
• 摘要

73.  Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011 Nov 10;365(19):1781-9.

• 全文
• 摘要

74.  Whitfield K, Rambaldi A, Wetterslev J, et al. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev. 2009;(4):CD007339.

• 全文
• 摘要

75.  De BK, Gangopadhyay S, Dutta D, et al. Pentoxifylline versus prednisone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009 Apr 7;15(13):1613-9.

• 全文
• 摘要

76.  Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000 Dec;119(6):1637-48.

• 摘要

77.  Tyagi P, Sharma P, Sharma BC, et al. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. Eur J Gastroenterol Hepatol. 2011 Mar;23(3):210-7.

• 摘要

78.  Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol. 2008 Mar;48(3):465-70.

• 摘要

79.  Mathurin P, Louvet A, Dao T, et al. Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6-month survival: results of the CORPENTOX trial. Hepatology. 2011;54:390A.

80.  Thursz MR, Richardson P, Allison M, et al; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015 Apr 23;372(17):1619-28.

• 全文
• 摘要

81.  Vergis N, Atkinson SR, Knapp S, et al. In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA. Gastroenterology. 2017 Apr;152(5):1068-77.

• 全文
• 摘要

82.  Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003 Apr;38(4):419-25.

• 摘要

83.  Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004 May;39(5):1390-7.

• 全文
• 摘要

84.  Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev. 2005;(2):CD002148.

• 全文
• 摘要

85.  Rambaldi A, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev. 2006;(4):CD003045.

• 全文
• 摘要

86.  Fede G, Germani G, Gluud C, et al. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev. 2011;(6):CD002800.

• 全文
• 摘要

87.  Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. 2012 [internet publication].

• 全文

88.  European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep;53(3):397-417.

• 全文
• 摘要

89.  Loomba R, Wesley R, Bain A, et al. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol. 2009 Apr;7(4):487-93.

• 摘要

90.  Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(suppl 6):vi1-vi12.

91.  European Association for the Study of the Liver. Clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.

92.  Kuiper JJ, van Buuren HR, de Man RA. Ascites in cirrhosis: a review of management and complications. Neth J Med. 2007;65(8):283-288.

93.  Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32(1):142-153.

94.  Bernardi M, Carceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172-1181.

• 摘要

95.  Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology. 1994 Nov;20(5):1115-20.

• 摘要

96.  Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol. 1996 Jul;91(7):1374-9.

• 摘要

97.  Keeffe EB. Comorbidities of alcoholic liver disease that affect outcome of orthotopic liver transplantation. Liver Transpl Surg. 1997 May;3(3):251-7.

• 摘要

98.  Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005 Feb;41(2):353-8.

• 全文
• 摘要

99.  Flannery BA, Garbutt JC, Cody MW, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res. 2004;28:1517-1523.

• 摘要

100.  Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370:1915-1922.

• 摘要

101.  Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1106-1117.

• 摘要

102.  Addolorato G, Leggio L, Agabio R, et al. Baclofen: a new drug for the treatment of alcohol dependence. Int J Clin Pract. 2006;60:1003-1008.

• 摘要

103.  Gache P, Hadengue A. Baclofen improves abstinence in alcoholic cirrhosis: Still better to come? J Hepatol. 2008;49:1083-1085.

• 摘要

104.  Barak AJ, Beckenhauer HC, Mailliard ME, et al. Betaine lowers elevated s-adenosylhomocysteine levels in hepatocytes from ethanol-fed rats. J Nutr. 2003;133:2845-2848.

• 全文
• 摘要

105.  Hanje AJ, Fortune B, Song M, et al. The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr Clin Pract. 2006;21:255-272.

• 摘要

106.  Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9:105-113.

• 摘要

107.  Parés A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol. 1998;28:615-621.

• 摘要

108.  Saller R, Brignoli R, Melzer J, et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed. 2008;15:9-20.

• 摘要

109.  Leggio L, Kenna GA, Ferrulli A, et al. Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. Hum Psychopharmacol. 2011;26:554-559.

• 摘要

110.  Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005 Aug;54(8):1174-9.

• 全文
• 摘要

111.  Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009 Oct;50(4):1175-83.

• 摘要

112.  Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;(9):CD002907.

• 摘要

113.  Gøtzsche PC, Hróbjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev. 2008;(3):CD000193.

• 摘要

114.  Garcia-Tsao G, Sanyal AJ, Grace ND, et al; Practice Guidelines Committee of American Association for Study of Liver Diseases; Practice Parameters Committee of American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol. 2007 Sep;102(9):2086-102.

• 摘要

115.  Yang J, Guo Z, Wu Z, et al. Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients. Cochrane Database Syst Rev. 2008;(2):CD005443.

• 摘要

116.  Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013 Jan 3;368(1):11-21.

• 全文
• 摘要

117.  Karwa R, Woodis CB. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother. 2009 Apr;43(4):692-9.

• 摘要

118.  Sagi SV, Mittal S, Kasturi KS, et al. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2010 May;25(5):880-5.

• 摘要

119.  Kim DK, Riley LE, Harriman KH, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66:136-138.

• 全文
• 摘要

120.  Speeg KV, Bay MK. Prevention and treatment of drug-induced liver disease. Gastroenterol Clin North Am. 1995;24:1047-1064.

• 摘要